ClinicalTrials.Veeva

Menu

The SIBERIA Trial (Acculink™ Versus CGuard™) (CAS)

M

Meshalkin Research Institute of Pathology of Circulation

Status

Completed

Conditions

Symptomatic Patients (Stenosis > 50%)
Patients With Aterosclerotic Carotid Stenosis
Asymptomatic Patients (Stenosis ≥80%)

Treatments

Device: CGuardTM™
Device: Stent Acculink ™

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT03488199
NRICP 9872

Details and patient eligibility

About

That the study will be carried out as it has the protocol instructions, respecting the applicable regulations for clinical investigations with medical devices and following the internationally accepted ethical standards

Full description

Independent Randomized Trial in Carotid Artery Revascularization Comparing the Stent (Acculink™) Versus the Mesh Covered Stent (CGuard™) was performed.

Ischemic lesions of brain after CAS were determined by MRI before and after treatment (2-3 days, 1 month).

Enrollment

100 patients

Sex

All

Ages

45 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  1. Consecutive patients 45-80 years old accepted for CAS following neurological consultation and qualification for the procedure according to center's routine practice.
  2. More than 6-month life expectancy
  3. Suitable clinical conditions for performing DW-MRI
  4. Written Informed consent approved by the Ethics Committee
  5. Subject agrees to all required follow-up procedures and visits

Exclusion Criteria:

  1. Currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints
  2. Recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure
  3. Hepatic active disease (bilirubin> 35 mmol / l) or renal insufficiency (serum creatinine > 2.5 mg/dL or glomerular filtration rate <60 ml / min)
  4. Recent evolving acute stroke within 30-days of study evaluation
  5. Myocardial infarction within 72 hours prior to carotid stenting procedure (CPK-MB > 3 times normal)
  6. Female patients of childbearing potential or known to be pregnant
  7. Any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia
  8. Patient on VKA or new oral anticoagulants

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)
Active Comparator group
Description:
50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
Treatment:
Device: Stent Acculink ™
Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))
Experimental group
Description:
50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
Treatment:
Device: CGuardTM™

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems